Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hyperparathyroidism, Secondary: later-stage trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Hyperparathyroidism, Secondary: 3 US clinical trials tracked, none currently recruiting.
Hyperparathyroidism, Secondary is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Nabi Biopharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition hyperparathyroidism-secondary
OPEN 0 | RECR 0% | LATE 2 | EARLY 0 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Hyperparathyroidism, Secondary has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hyperparathyroidism, Secondary on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hyperparathyroidism, Secondary is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis
Amgen
NCT02102204
CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients
Nabi Biopharmaceuticals
NCT00211939
Oral Paricalcitol in Kidney Transplant Recipients
Mayo Clinic
NCT00587158
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hyperparathyroidism, Secondary records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hyperparathyroidism, Secondary trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hyperparathyroidism, Secondary page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Hyperparathyroidism, Secondary trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Nabi Biopharmaceuticals sponsors the most Hyperparathyroidism, Secondary trials on record, review their full trial history before evaluating a specific study. See Nabi Biopharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hyperparathyroidism, Secondary condition card totals 3 registered trials; most-linked intervention sevelamer; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.